Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Labetalol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 13/20 | 1.00 |
| ▸ | ADRA1A known ✓ | P35348 | 13/20 | 1.00 |
| ▸ | ADRB2 known ✓ | P07550 | 13/20 | 1.00 |
| ▸ | ADRA1D known ✓ | P25100 | 12/20 | 1.00 |
| ▸ | ADRA1B known ✓ | P35368 | 12/20 | 1.00 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 1.00 |
| ▸ | ADRB3 known ✓ | P13945 | 11/20 | 0.98 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.98 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Labetalol SCHEMBL29687428 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL3499242 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL7273474 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL4582 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL10356800 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL10882744 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Dilevalol SCHEMBL79468 | 1.00 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL41230 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL10450118 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B | |
| Labetalol SCHEMBL9614383 | 0.99 | ADRB1 (1.00) | ADRB1ADRA1AADRB2ADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7087 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691556-A2 | HUMANIZED ANTI-ACTH ANTIBODIES AND USE THEREOF | H. Lundbeck A/S (DK) | 2026-02-11 | — | — | EP | claimed |
| US-20250302887-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2025-10-02 | — | — | US | claimed |
| US-20250264469-A1 | METHODS FOR IMPROVING OUTCOMES FOR HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS AT RISK FOR BRONCHIOLITIS OBLITERANS SYNDROME | CHILDREN'S HOSPITAL MEDICAL CENTER | 2025-08-21 | — | — | US | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| US-20250090602-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2025-03-20 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20240299465-A1 | AMMONIA OXIDIZING MICROORGANISMS FOR THE REGULATION OF BLOOD PRESSURE | AOBIOME LLC (US) | 2024-09-12 | — | — | US | claimed |
| CN-118526590-A | Application of neuropeptide Y as cough medicine target point | 广州医科大学附属第一医院（广州呼吸中心） | 2024-08-23 | — | — | CN | claimed |
| CN-118490632-A | Stable labetalol hydrochloride injection and preparation method thereof | 遂成药业股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| US-20240252528-A1 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | REGENERON PHARMACEUTICALS, INC. | 2024-08-01 | — | — | US | claimed |
| US-4885173-A | ALLOWING PATIENT TO SUCK LOLLIPOP CONTAINING DRUG, WHICH IS RAPIDLY ABSORBED; REMOVING WHEN SYMPTOMS HAVE BEEN RELIEVED | UNIVERSITY OF UTAH (US) | 1989-12-05 | — | — | US | claimed |
| EP-0318889-A2 | Method for treatment of dyslipidemia in humans | SCHERING CORPORATION (US) | 1989-06-07 | — | — | EP | claimed |
| US-4788183-A | Method for treatment of dyslipidemia in humans | SCHERING CORPORATION (US) | 1988-11-29 | — | — | US | claimed |
| EP-0266707-A2 | Sustained release labetalol tablet | SCHERING CORPORATION (US) | 1988-05-11 | — | — | EP | claimed |
| EP-0259136-A2 | Transdermal delivery device having a rate controlling adhesive | ALZA CORPORATION (US) | 1988-03-09 | — | — | EP | claimed |
| US-4659714-A | PROLONGATION WITH VASOCONSTRICTORS; REVERSAL WITH ADRENERGIC BLOCKING AGENTS | DENTSPLY, LTD. (GB) | 1987-04-21 | — | — | US | claimed |
| US-4559222-A | MINERAL OIL POLYISOBUTYLENE, COLLOIDAL SILICON DIOXIDE MIXTURE; CONTROLLED RELEASE | ALZA CORPORATION (US) | 1985-12-17 | — | — | US | claimed |
| EP-0160191-A1 | Kit for treating mammals | Dentsply Limited (GB) | 1985-11-06 | — | — | EP | claimed |
| US-4328213-A | HYPOTENSIVE AGENTS, ANTIARRHTHYMIA AGENTS | SCHERING CORPORATION (US) | 1982-05-04 | — | — | US | claimed |
| US-4256108-A | Microporous-semipermeable laminated osmotic system | ALZA CORPORATION (US) | 1981-03-17 | — | — | US | claimed |